Ondine Biomedical Inc.
OBI.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £2,049 | £1,203 | £638 | £2,569 |
| % Growth | 70.3% | 88.6% | -75.2% | – |
| Cost of Goods Sold | £728 | £500 | £351 | £1,315 |
| Gross Profit | £1,321 | £703 | £287 | £1,254 |
| % Margin | 64.5% | 58.4% | 45% | 48.8% |
| R&D Expenses | £9,219 | £5,140 | £6,280 | £4,982 |
| G&A Expenses | £9,934 | £8,010 | £10,909 | £12,970 |
| SG&A Expenses | £11,011 | £9,798 | £12,310 | £13,334 |
| Sales & Mktg Exp. | £1,077 | £1,788 | £1,401 | £364 |
| Other Operating Expenses | £535 | £570 | £460 | £458 |
| Operating Expenses | £20,765 | £15,508 | £19,050 | £18,774 |
| Operating Income | -£19,444 | -£14,805 | -£18,763 | -£17,520 |
| % Margin | -949% | -1,230.7% | -2,940.9% | -682% |
| Other Income/Exp. Net | £346 | £393 | -£609 | -£32,565 |
| Pre-Tax Income | -£19,098 | -£14,412 | -£19,372 | -£50,085 |
| Tax Expense | £0 | £0 | £0 | £0 |
| Net Income | -£19,098 | -£14,412 | -£19,372 | -£50,085 |
| % Margin | -932.1% | -1,198% | -3,036.4% | -1,949.6% |
| EPS | -0.07 | -0.073 | -0.1 | -0.26 |
| % Growth | 4.2% | 26.9% | 61.5% | – |
| EPS Diluted | -0.07 | -0.073 | -0.1 | -0.26 |
| Weighted Avg Shares Out | 274,601 | 197,112 | 194,588 | 194,585 |
| Weighted Avg Shares Out Dil | 274,601 | 197,112 | 194,588 | 194,585 |
| Supplemental Information | – | – | – | – |
| Interest Income | £32 | £242 | £191 | £0 |
| Interest Expense | £47 | £38 | £30 | £1,212 |
| Depreciation & Amortization | £565 | £587 | £493 | £514 |
| EBITDA | -£18,486 | -£13,787 | -£18,849 | -£48,359 |
| % Margin | -902.2% | -1,146.1% | -2,954.4% | -1,882.4% |